Pfizer has changed its research and development (R&D) leadership team. The most prominent move includes the appointment of Chris Boshoff, MD, PhD, as Chief Oncology Research and Development Officer and EVP. He will be responsible for the entire oncology pipeline, reporting to CEO Albert Bourla. Boshoff has previously worked on Pfizer’s oncology and rare diseases portfolios.
Furthermore, Mikael Dolsten, MD, PhD, will lead “all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas” as Chief Scientific Officer, President, Pfizer Research & Development. Boshoff will also lead the integration planning for Seagen’s medicines and team after the anticipated $43 billion acquisition of Seagen.
To read more, click here.
[Source: MM+M, July 27th, 2023]